Skip to Content
Merck
CN

Recalcitrant hypocalcaemia in autoimmune enteropathy.

Pediatrics (2014-11-19)
Myfanwy Geyer, Jan Fairchild, David Moore, Lynette Moore, Paul Henning, Elaine Tham
ABSTRACT

Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy syndrome is a monogenic disorder associated with autoimmune destruction of both endocrine and nonendocrine tissues. The classic triad includes candidiasis, hypoparathyroidism, and Addison disease. Up to 25% of patients with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy syndrome also have gastrointestinal manifestations, which can have an impact on the management of other aspects of the disease. The management of the case discussed was challenging because of the complex interplay between the manifestations and treatment of his hypoparathyroidism, Addison disease, and autoimmune enteropathy. Attempts at management of hypocalcemia were largely unsuccessful until the introduction of immunosuppressive therapy for autoimmune enteropathy. This case supports early consideration of immunosuppression in this condition.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Azathioprine, ≥98%
Supelco
1α,25-Dihydroxyvitamin D3 solution, 5 μg/mL in ethanol, ampule of 1 mL, certified reference material, Cerilliant®
Calcitriol, European Pharmacopoeia (EP) Reference Standard
Azathioprine, European Pharmacopoeia (EP) Reference Standard
Supelco
Azathioprine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
1α,25-Dihydroxyvitamin D3, ≥99% (HPLC)
Sigma-Aldrich
1α,25-Dihydroxyvitamin D3, ≥97.0% (HPLC)
Supelco
Cyclosporin A solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Calcium citrate tetrahydrate, 99%